In addition, Ulaner and colleagues published a series of articles about 89Zr-trastuzumab243,244 and 89Zr-pertuzumab245,246 to identify HER2-positive metastases in patients with HER2-negative primary breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.